← Back to Search

CAR T-cell Therapy

UCARTCS1A for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Cellectis S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Other criteria may apply.
No previous treatment with investigational gene targeting CS1 or chimeric antigen receptor therapy targeting CS1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective for people with multiple myeloma who have relapsed or are refractory.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
There may be additional requirements that you need to meet to be eligible for the study.
Select...
You have not been treated before with experimental gene targeting CS1 or chimeric antigen receptor therapy targeting CS1.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of UCARTCS1A
Secondary outcome measures
Duration of Response
Overall Survival
Progression Free Survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment1 Intervention
Several tested doses of UCARTCS1A until the Maximum Tolerated Dose (MTD) is identified.

Find a Location

Who is running the clinical trial?

Cellectis S.A.Lead Sponsor
5 Previous Clinical Trials
186 Total Patients Enrolled

Media Library

UCARTCS1A (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04142619 — Phase 1
Multiple Myeloma Research Study Groups: Dose Escalation
Multiple Myeloma Clinical Trial 2023: UCARTCS1A Highlights & Side Effects. Trial Name: NCT04142619 — Phase 1
UCARTCS1A (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04142619 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this trial currently open?

"According to the information hosted on clinicaltrials.gov, this medical trial is still looking for participants. It was initially posted in November of 2019 and then last updated in August 2022."

Answered by AI

To what extent is the population participating in this trial?

"Affirmative. According to clinicaltrials.gov information, this research project is presently seeking participants with the original listing being posted on November 21st 2019 and most recently modified by researchers on August 30th 2022. A total of 18 individuals from 7 distinct medical sites are required for this study."

Answered by AI

Does this clinical trial accept participants aged 25 or older?

"This trial is enrolling patients aged 18 to 64. Subsequently, there are 40 trials for minors and 793 more for elderly participants."

Answered by AI

How many research facilities are administering this trial?

"The trial is currently enrolling participants at 7 different study sites, located in San Antonio, Denver and Houston as well as several other spots. To minimise travel costs for yourself, select the closest available location to you."

Answered by AI

Who is eligible to partipate in this trial?

"The prerequisites to enter this clinical trial are as follows: a diagnosis of relapsed or refractory multiple myeloma and an age between 18-64. At present, the team is recruiting 18 volunteers for the study."

Answered by AI

Has the Food and Drug Administration sanctioned UCARTCS1A?

"With limited data supporting efficacy and safety, UCARTCS1A is given a score of 1 on the risk scale."

Answered by AI
~2 spots leftby Mar 2025